Seven months have passed since federal appellate judges in New York openly questioned whether a lower court went too far in shutting down the Tylenol autism lawsuit litigation — and the Second Circuit still has not issued its ruling. As of June 28, 2026, MDL 3043 sits at the most consequential crossroads in consumer product mass tort law, with the FDA moving toward updated pregnancy warning labels, state courts accelerating filings, and an estimated universe of potentially more than 100,000 claimants watching a single appellate decision that could reshape everything. Here is what families, advocates, and legal observers need to know right now.
The MDL 3043 Collapse — And What Triggered the Appeal
The federal Tylenol autism lawsuit consolidation — formally known as In re Acetaminophen – ASD-ADHD Products Liability Litigation, docket 1:22-md-3043 (DLC) — was created by the Judicial Panel on Multidistrict Litigation on October 5, 2022, and assigned to Judge Denise Cote in the Southern District of New York. At its core, the litigation alleges that children developed autism spectrum disorder (ASD) and/or ADHD following their mothers’ use of acetaminophen — the active ingredient in Tylenol and hundreds of store-brand equivalents — during pregnancy.
The MDL encompassed claims against a sweeping roster of defendants: Johnson & Johnson, its consumer health spinoff Kenvue, and major retailers including Walmart, CVS, Walgreens, Costco, Target, Rite Aid, Dollar Tree, and Family Dollar. At its peak the docket held approximately 500 federal claims, with legal observers estimating the broader potential claimant pool in the tens of thousands.
The litigation unraveled in September 2023, when Judge Cote issued a sweeping Daubert ruling excluding all five of the plaintiffs’ general causation experts, concluding they had not employed a “reliable application of scientific methods” to establish a causal link between prenatal acetaminophen exposure and autism or ADHD. Without expert causation testimony, plaintiffs could not proceed. In August 2024, Judge Cote granted summary judgment for the defendants, effectively dismissing all approximately 500 federal claims. Plaintiffs immediately appealed to the United States Court of Appeals for the Second Circuit.
November 2025 Oral Arguments: Two Judges Signal Deep Skepticism of the Exclusion
On November 17, 2025, a three-judge Second Circuit panel heard oral arguments in the appeal — and what unfolded gave plaintiffs’ attorneys reason for cautious optimism. Two of the three judges openly questioned whether Judge Cote had been “too aggressive” in excluding the plaintiffs’ expert evidence. One judge specifically noted that plaintiffs’ lead expert, Dr. Andrea Baccarelli of Harvard University, appeared to clearly explain his scientific reasoning. A second judge went further, suggesting that a jury — not a judge at the Daubert gatekeeping stage — should have been permitted to evaluate and weigh the evidence.
Those are not throwaway comments. In appellate oral arguments, judicial skepticism of that specificity and directness is a meaningful signal. Attorneys tracking the Tylenol autism lawsuit litigation have described the November hearing as the single most important moment in the case since the MDL was created. If the Second Circuit reverses Judge Cote’s Daubert ruling and reinstates the MDL, the litigation could surge well past 100,000 claims. If the exclusion is upheld, state courts become the primary — and likely only — viable litigation path for affected families.
As of today, June 28, 2026, no ruling has been issued. The longer the silence, the more attorneys on both sides acknowledge the panel may be wrestling with a genuinely close question about the boundaries of trial court Daubert discretion. For families weighing their legal options, this remains the defining inflection point of 2026. You can use a medical malpractice calculator as a starting-point reference for understanding how courts approach damage valuations in defective drug claims, though every individual case turns on its specific facts.
The FDA Factor: When the Regulator Relies on the Expert the Court Excluded
Perhaps the most striking development of 2026 in the Tylenol autism lawsuit saga is the FDA’s parallel movement on acetaminophen pregnancy labeling — and the direct collision it creates with Judge Cote’s reasoning.
In late 2025, the U.S. Food and Drug Administration announced plans to update labeling language for acetaminophen products to reflect emerging research signals regarding possible connections to neurodevelopmental conditions such as autism and ADHD in children exposed in utero. The FDA has been careful to note that no definitive causal link has been confirmed, but the agency’s willingness to move toward a warning label update is itself a significant regulatory acknowledgment that the science cannot simply be dismissed.
The irony — and the legal opportunity plaintiffs have seized — is that the FDA’s advisory and its internal review relied substantially on the research of Dr. Andrea Baccarelli: the same Harvard scientist whose methodology Judge Cote found insufficiently reliable to present to a jury. Plaintiffs’ attorneys formally submitted a letter to the Second Circuit urging the panel to consider the FDA’s actions as new evidence directly bearing on the reliability question at the heart of the Daubert appeal. Whether the appellate court weighs that submission in its final ruling remains unknown, but it reframes the central question: if the nation’s top drug regulator finds Baccarelli’s research credible enough to trigger a label change, how unreliable could it truly be?
State Courts, the Texas AG Case, and the Expanding Legal Battlefield
While the federal appeal grinds forward, the Tylenol autism lawsuit litigation is not standing still at the state level. Attorneys representing affected families have been aggressively filing in state courts — most actively in Florida, Illinois, and Pennsylvania as of June 2026 — where Daubert or Frye standard variations may treat expert admissibility differently than the federal standard applied by Judge Cote.
State court litigation carries distinct strategic value: state judges are not bound by the Second Circuit’s eventual ruling on the federal Daubert question, and several state courts operate under evidentiary frameworks that afford plaintiffs more flexibility in presenting expert testimony to juries. Legal analysts project significant state-court momentum in the second half of 2026 regardless of how the Second Circuit rules, as the volume of new state filings has been accelerating month over month.
Separately, a lawsuit filed by Texas Attorney General Ken Paxton against Kenvue and Johnson & Johnson — alleging deceptive trade practices in connection with acetaminophen marketing — survived a motion to dismiss, keeping that enforcement action alive and adding a consumer protection dimension to the broader litigation landscape. The Texas AG case is notable because it does not require the same expert causation threshold that sank the federal MDL; it is rooted in allegations about what defendants knew, when they knew it, and how they communicated risk to consumers.
On the defense side, defendants continue to argue that epidemiological studies showing correlations between acetaminophen and autism are plagued by confounders, including maternal fever, underlying genetics, and prenatal infections — conditions that independently elevate autism risk and that also prompt acetaminophen use, making causal isolation extremely difficult. A Lancet study published in 2026 reviewed 43 high-quality studies and concluded no causal link could be established, providing defendants with updated ammunition for their scientific arguments. As of June 28, 2026, no settlements have been finalized and no jury verdicts have been reached in any Tylenol autism lawsuit case. If the MDL is revived, per-claim settlement projections range from $300,000 to $600,000 depending on severity and supporting documentation. Families with questions about general injury valuation methodology can explore a personal injury settlement calculator for educational context, understanding that mass tort valuations involve complex litigation-specific factors.
Key Statistics: Tylenol Autism Lawsuit at a Glance (June 2026)
| Data Point | Detail | Source |
|---|---|---|
| MDL Created | October 5, 2022 | JPML |
| Federal Claims Dismissed | Approximately 500 (August 2024) | SDNY Docket 1:22-md-3043 |
| Oral Arguments Date | November 17, 2025 | Second Circuit Court of Appeals |
| Second Circuit Ruling Status | Pending as of June 28, 2026 | Second Circuit Docket |
| Projected Claims if MDL Revived | 100,000+ | Legal analyst projections |
| Estimated Per-Claim Settlement Range | $300,000–$600,000 | Mass tort litigation estimates |
| Settlements Finalized | None as of June 28, 2026 | Public court records |
| Jury Verdicts Issued | None as of June 28, 2026 | Public court records |
| Active State Court Jurisdictions | Florida, Illinois, Pennsylvania + others | Attorney filings, 2026 |
| FDA Label Update Status | In progress — pregnancy warning under revision | FDA.gov |
What Families Should Know Right Now
If your child was diagnosed with autism spectrum disorder or ADHD and you used acetaminophen during pregnancy, the legal landscape in 2026 is fluid but not closed. The federal MDL path is frozen pending the Second Circuit ruling, but state court options are actively expanding. Statutes of limitations vary significantly by state, and some discovery rules — particularly those governing when a plaintiff “knew or should have known” about a potential connection — mean that waiting to explore options carries real risk.
The Tylenol autism lawsuit litigation involves scientifically contested claims, and the science itself continues to evolve in real time. The defense position is not frivolous — the Lancet 2026 review is a serious body of work, and confounders are a genuine methodological challenge. But the FDA’s parallel movement toward updated labeling, and the Second Circuit’s apparent skepticism of the exclusion ruling, signal that the science has not been settled by a single district court Daubert order. Families considering their options should also be aware that, because this litigation involves potential neurodevelopmental injuries to children, damage calculations can be uniquely complex — involving lifetime care costs, educational needs, and quality-of-life metrics that differ substantially from standard personal injury frameworks.
Frequently Asked Questions: Tylenol Autism Lawsuit 2026
What is the current status of the Tylenol autism lawsuit MDL as of June 2026?
The federal MDL — MDL 3043, formally In re Acetaminophen – ASD-ADHD Products Liability Litigation — was dismissed in August 2024 after Judge Denise Cote of the Southern District of New York excluded all five plaintiffs’ general causation experts under Daubert and subsequently granted summary judgment to defendants. Plaintiffs appealed to the Second Circuit Court of Appeals, which heard oral arguments on November 17, 2025. As of June 28, 2026, the Second Circuit has not issued a ruling. Two of three appellate judges expressed open skepticism during oral arguments about whether the lower court was overly aggressive in excluding expert testimony, making this ruling the most closely watched development in mass tort litigation in 2026.
What happens to the Tylenol autism lawsuit if the Second Circuit reverses the Daubert ruling?
A reversal would reopen the federal MDL and allow plaintiffs’ expert causation testimony — including that of Dr. Andrea Baccarelli of Harvard — to proceed toward trial. Legal analysts estimate that a reversal could cause the MDL to surge past 100,000 claims as families who have been waiting for appellate clarity move forward with federal filings. It would also significantly strengthen parallel state court cases and potentially prompt renewed settlement discussions with defendants including Kenvue, Johnson & Johnson, and major retail pharmacy chains. Estimated per-claim settlement values, if the MDL is revived and cases advance, have been projected in a range of $300,000 to $600,000 depending on individual claim characteristics.
What is the significance of the FDA’s acetaminophen pregnancy label update to the lawsuit?
The FDA’s movement toward an updated acetaminophen pregnancy warning label is legally and scientifically significant for several reasons. First, it represents a federal regulatory acknowledgment that the body of research connecting prenatal acetaminophen exposure to possible neurodevelopmental effects is serious enough to warrant consumer notification — even absent a confirmed causal link. Second, and critically for the litigation, the FDA’s advisory review relied substantially on the research of Dr. Andrea Baccarelli, the same expert whose methodology Judge Cote found unreliable in her Daubert ruling. Plaintiffs formally submitted the FDA’s actions to the Second Circuit as new evidence, arguing that if the nation’s top drug regulator treats Baccarelli’s science as credible enough to drive label changes, the lower court’s reliability finding deserves serious scrutiny. The FDA’s drug safety communications page tracks ongoing regulatory updates.
Are there active Tylenol autism lawsuit cases outside of the federal MDL in 2026?
Yes. State court litigation has been accelerating significantly in 2026, with active filings in Florida, Illinois, Pennsylvania, and other jurisdictions. State courts are not bound by Judge Cote’s Daubert ruling or the Second Circuit’s eventual decision on the federal standard, and some states apply different evidentiary frameworks — such as the Frye standard — that may be more permissive regarding the admission of plaintiffs’ expert testimony. Attorneys project substantial state-court momentum in the second half of 2026 regardless of the federal appellate outcome. Additionally, the Texas Attorney General’s lawsuit against Kenvue and Johnson & Johnson, alleging deceptive trade practices, survived a motion to dismiss and represents a separate enforcement track that does not depend on the causation expert admissibility question at the center of the federal MDL dispute.
Who are the defendants in the Tylenol autism lawsuit, and has any money been paid to families?
The defendants named in the MDL and related state court litigation include Johnson & Johnson, its consumer health spinoff Kenvue (which now holds the Tylenol brand), and major retail pharmacy chains that sold store-brand acetaminophen products: Walmart, CVS, Walgreens, Costco, Target, Rite Aid, Dollar Tree, and Family Dollar. As of June 28, 2026, no settlements have been finalized and no jury verdicts have been reached in any Tylenol autism lawsuit case. The litigation has not yet reached a compensation phase for any plaintiff. The path to potential compensation depends substantially on the Second Circuit’s pending ruling and the continued development of state court cases through the remainder of 2026 and beyond.
This content is provided for informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding your specific legal situation.
Related reading: Maine Surgical Artery Severance Verdict: $23.1 Million Award For Permanent Paralysis From Post-Surgery Negligence
Related reading: Medical Malpractice Wrongful Death Damages: What The 2026 MICRA Cap Actually Limits — And What It Doesn’t
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.